Company intelligence / Profile preview

Sixty Degrees

Washington, District of Columbia, United States

Ownership: Private
Development stage: Other

Overview

60 Degrees Pharmaceuticals has an FDA-approved small-molecule drug tafenoquine (marketed as ARAKODA) for malaria prophylaxis and is running Phase 2 and expanded-access studies of tafenoquine for babesiosis, as well as early pilot studies of intravenous tafenoquine for Candida infections and an antiviral candidate for viral diseases.[1][2][4]

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

GoodRx (commercial access partnership for ARAKODA savings program)[4]

Beyond the preview

Go deeper on Sixty Degrees.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sixty Degrees.

Explore the full profile